Evidence map›Paper›PMID 36986548›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Novel

Arsyangela Verena, Hsiou-Ting Kuo, Helen Merkens, Jutta Zeisler, Shreya Bendre, Antonio A W L Wong, François Bénard, Kuo-Shyan Lin

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. [Diagnostics (Basel, Switzerland) · 2024
    Article
  3. Synthesis and Preclinical Evaluation of Two NovelMolecules (Basel, Switzerland) · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Arsyangela VerenaDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0003-4276-2022
Hsiou-Ting KuoDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Helen MerkensDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Jutta ZeislerDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Shreya BendreDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Antonio A W L WongDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0003-4617-9248
François BénardDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0001-7995-3581
Kuo-Shyan LinDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0002-0739-0780
Terry Fox Research Institute · CAUniversity of British Columbia · CA

Funding

CIHR PJT-180300
6 · The paper itself

Abstract

Compared to quinoline-based fibroblast activation protein (FAP)-targeted radiotracers, pyridine-based FAP-targeted tracers are expected to have faster pharmacokinetics due to their smaller molecular size and higher hydrophilicity, which we hypothesize would improve the tumor-to-background image contrast. We aim to develop

Indexed as

FAPI-04FAP inhibitorsfibroblast activation proteinGallium-68PET/CTpyridine-based pharmacophore

Identifiers

PMID36986548
PMCPMC10057391
OpenAlexW4327736542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.